Sanyou Bio Raises Nearly $15M to Scale AI Drug Discovery

Nathan Brooks

Sanyou Bio said it had completed a Series C financing of nearly $15 million (RMB 100 million), bringing cumulative funding to approximately $45 million (RMB 300 million). Zero2IPO Industry Investment, an investment platform managed by Zero2IPO Group, funded the round exclusively. The investment represents about one-third of the biotechnology company’s disclosed capital to date.

The Shanghai-based biotechnology company develops AI-powered drug discovery technologies and says the money will expand Sanyou Bio’s integrated drug research and development platform. The expansion includes antibody discovery technology, AI-driven laboratory systems and a collaborative innovation network. It will also increase investment in drug candidates and commercialization opportunities.

The company’s stated goal is to improve early-stage drug discovery and help pharmaceutical companies translate research findings into therapeutic development programs. Sanyou Bio says the partnership will deepen its AI research, expand its drug development pipeline and strengthen collaboration with pharmaceutical partners globally.

Dr. Guojun Lang, founder and CEO of Sanyou Bio, said: “We look forward to working hand in hand with partners around the world to accelerate innovative drug development and bring greater benefits to patients worldwide.”

What does the funding change for drug developers?

For pharmaceutical and biotechnology partners, the immediate change is added capacity across molecular screening, laboratory validation and external collaboration. Sanyou Bio says the capital will develop those tools, invest more in drug candidates and support commercialization. Its stated benefit is greater early-stage efficiency and less inefficiency in moving research findings toward therapeutic development programs.

A three-stage funding history

Sanyou Bio completed its Series A financing in May 2020, Series B in June 2021 and Series B+ in August 2022. The company describes the latest investment as another step toward expanding technology capabilities and commercial relationships across the pharmaceutical industry.

Three connected platforms

According to Sanyou Bio, the AI-Super-Trillion Antibody Library, also known as AI-STAL, contains a proprietary molecular library of approximately 11 trillion candidates. It supports the discovery and evaluation of molecules that could form the foundation of future therapeutic products.

According to Sanyou Bio, the Sanyou AI-Drug Accelerator, or SAI-DA, combines computational drug discovery with experimental laboratory capabilities. It integrates dozens of AI algorithms with wet-laboratory processes across various stages of preclinical research, connecting molecular design, experimental validation and development activities in one workflow.

Sanyou Bio says Clicklinks serves as an open innovation platform connecting pharmaceutical companies, biotechnology developers and other research partners. The company says it is intended to support collaboration and accelerate the progression of drug discovery projects.

Sanyou Bio presents the three technologies as an integrated system spanning early-stage molecular identification, laboratory research and advancement toward clinical development. The company believes combining AI algorithms with physical laboratory capabilities can reduce inefficiencies associated with traditional drug research.

Scale behind the platform

According to the company’s announcement, Sanyou Bio has established partnerships with more than 2,000 pharmaceutical and biotechnology organizations worldwide. Its commercial and research activity includes more than 100 collaborative research and development projects and over 1,000 drug discovery and stage-specific development assignments.

More than 10 innovative drug projects associated with those collaborations have advanced into clinical research, according to Sanyou Bio. The company has filed more than 180 invention patent applications, with over 30 patents granted.

Sanyou Bio says it operates and plans more than 20,000 square meters of research, development and manufacturing facilities. Its international business network spans Asia, North America, Europe and other regions.

According to Zero2IPO Industry Investment, the platform brings investment experience across healthcare, frontier technologies, energy and other industrial sectors. It manages nearly $3 billion (RMB 20 billion) in assets and has supported numerous technology and healthcare companies.

Lang also said:

“innovative drug development is a systematic undertaking that requires long-term investment, technological accumulation, and industrial collaboration. Sanyou Bio has always remained committed to its mission of ‘To make it easy to develop new drugs worldwide.’

Through technological innovation and the development of systematic capabilities, we aim to help the industry improve the efficiency of innovative drug R&D, lower barriers to innovation, and empower more partners in drug development.”

“This financing represents recognition of our technological achievements and strategic direction to date, while also providing important momentum as we move into our next stage of development.

Going forward, we will continue to invest in the development of our three core platforms—AI-STAL, SAI-DA, and Clicklinks—leveraging AI to empower innovative drug R&D, enhancing R&D efficiency through platform synergy, and further focusing on pipeline-driven drug translation.

Our goal is to transform our technological strengths into innovative outcomes with genuine clinical and industrial value.”

Min Yang, managing partner of Zero2IPO Group and Zero2IPO Industry Investment, said:

“innovative drug development is a field characterized by high technological barriers, deep professional expertise, and long-term value creation. As artificial intelligence and life sciences continue to converge, the industry is facing increasingly demanding requirements for efficient, intelligent, and systematic drug development capabilities.”

“Sanyou Bio has established a systematic strategic framework encompassing early-stage molecular discovery, R&D acceleration, and the development of an open innovation ecosystem. The company has built a solid foundation in technology platforms, collaborative R&D, and industrial resource integration.

We are confident in its long-term potential to leverage AI technology to improve drug development efficiency, expand the boundaries of innovation through platform synergy, and unlock industrial value through the translation of innovative drug pipelines.”

“Through this investment, we look forward to supporting Sanyou Bio in further deepening its technological innovation and business development, and working together with the company to promote high-quality growth across the innovative drug R&D industry.”

The next measurable outcome for Sanyou Bio is whether its 11-trillion-candidate library and 2,000-plus partner network produce more projects in clinical research. For drug developers, the practical measure will be how quickly candidates move through the linked discovery, laboratory and collaboration workflow.